Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Receivables (2016 - 2025)

Jaguar Health (JAGX) has disclosed Receivables for 11 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 15.16% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 15.16% increase, with the full-year FY2024 number at $1.6 million, down 24.59% from a year prior.
  • Receivables was $1.5 million for Q3 2025 at Jaguar Health, up from $1.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $5.9 million in Q1 2021 to a low of $1.3 million in Q3 2024.
  • A 5-year average of $2.2 million and a median of $1.8 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: surged 445.26% in 2021, then plummeted 61.95% in 2022.
  • Jaguar Health's Receivables stood at $2.1 million in 2021, then grew by 15.07% to $2.5 million in 2022, then decreased by 11.47% to $2.2 million in 2023, then fell by 24.59% to $1.6 million in 2024, then dropped by 8.68% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Receivables are $1.5 million (Q3 2025), $1.3 million (Q2 2025), and $1.4 million (Q1 2025).